CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 53 enrolled
Drug / intervention
TKI258drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01379534
NCT01379534Phase 2Completed
CompareCT.gov

A Phase II, Open-label, Single-arm, Non-randomized, Multi-center Study to Evaluate the Efficacy of Oral TKI258 as Second-line Therapy in Patients With Either FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Novartis Pharmaceuticals·interventional·Posted Jun 23, 2011·Updated May 20, 2015

In Brief

A Phase 2 clinical trial evaluating TKI258 for Solid Tumors and Advanced Endometrial Cancer and 3 related conditions. Completed, enrolled 53 participants across 45 sites in 7 countries.

Detailed Summary

This is a prospective, multi-center, open-label, single-arm, non-randomized, Phase II study to evaluate the efficacy and safety of TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and/or metastatic endometrial cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors and Advanced Endometrial Cancer, Endometrial Cancer, Second-line Treatment, VEGF
CountriesBrazil, Italy, New Zealand, South Korea, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 23, 2011
Enrollment StartNov 1, 2011
Primary CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.0 years ago

Interventions

TKI258drug